Mental Health Care (UK) Ltd

Mental Health Care UK (MHC) is one of the UK’s top 50 providers of support to individuals with learning disabilities,mental health issues, behaviours that challenge and autism. In our calm and safe residential homes and hospitals we believe in a research based approach to our services. Residents with learning disabilities, behaviours that challenge, mental health issues, and autism will benefit from an approach that uses Active Support, Person Centred Planning and Positive Behavioural Support to enable our residents to be in control, make decisions and achieve what’s important for them.

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us

Events

Related News

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

news image

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

news image

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More

HOW DOES AVID BIOSERVICES INC (CDMO) STOCK COMPARE TO OTHERS IN BIOTECHNOLOGY?

InvestorsObserver | April 22, 2020

news image

Avid Bioservices Inc (CDMO) is around the top of the Biotechnology industry according to InvestorsObserver. CDMO received an overall rating of 68, which means that it scores higher than 68 percent of all stocks. Avid Bioservices Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 7 out of the 148 industries. What do These Ratings Mean? Finding the best stocks can be tricky. It isn’t easy to compare comp...

Read More

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

news image

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More
news image

PHARMA MAR STARTS APLICOV-PC CLINICAL TRIAL WITH APLIDIN FOR TREATMENT OF COVID-19

PharmaMar | April 28, 2020

PharmaMar (MSE: PHM) has announced the start of the APLICOV-PC clinical trial with Aplidin® (plitidepsin), for the treatment of patients with COVID-19, which has been authorized by the Spanish Medicines and Healthcare Products Agency (AEMPS). This is a multicenter, randomized, parallel, open-label study to evaluate the safety profile and efficacy of three doses of plitidepsin in patients with COVID-19 requiring hospital admission. Three hospitals from Madrid (Spain) will participate in the s...

Read More
news image

CUREVAC BIDS TO DEVELOP FIRST MRNA CORONAVIRUS VACCINE

Labiotech | February 03, 2020

RNA vaccine developer CureVac will receive a grant of up to €8.3M from a global partnership to develop an mRNA vaccine against the new coronavirus strain from China. The agreement follows on from an existing collaboration launched in 2019, when the Coalition for Epidemic Preparedness Innovations, or CEPI, granted CureVac €30M to develop facilities that can ‘print’ mRNA vaccines. The aim of the new grant is to help CureVac’s preclinical-stage mRNA vaccine for the coron...

Read More
news image

HOW DOES AVID BIOSERVICES INC (CDMO) STOCK COMPARE TO OTHERS IN BIOTECHNOLOGY?

InvestorsObserver | April 22, 2020

Avid Bioservices Inc (CDMO) is around the top of the Biotechnology industry according to InvestorsObserver. CDMO received an overall rating of 68, which means that it scores higher than 68 percent of all stocks. Avid Bioservices Inc also achieved a score of 76 in the Biotechnology industry, putting it above 76 percent of Biotechnology stocks. Biotechnology is ranked 7 out of the 148 industries. What do These Ratings Mean? Finding the best stocks can be tricky. It isn’t easy to compare comp...

Read More
news image

LYGENESIS ANNOUNCES FOUR PEER-REVIEWED PAPERS ARE PUBLISHED ON ITS ORGAN REGENERATION TECHNOLOGY

LyGenesis | August 28, 2020

LyGenesis, Inc., a biotechnology company focused on regenerative medicine, announced today that four peer-reviewed papers have been published on its organ regeneration technology. LyGenesis' lead development asset is liver regeneration, which was the focus of the first two papers. Development of Ectopic Livers by Hepatocyte Transplantation into Swine Lymph Nodes by Fontes et al. was published this month in Liver Transplantation, demonstrating that functional mini-livers could be grown using ...

Read More

Resources

Events

C-Suite On Deck

Responsive image

Feature market insights and perspectives from top C-Level executives, elite technology influencers and thought leaders from your company here. This signature initiative has garnered immense support...

Contact Us